

August 3, 2016



# OPKO to Announce Second Quarter Operating and Financial Results on August 8, 2016

MIAMI--(BUSINESS WIRE)-- **OPKO Health, Inc. (NASDAQ:OPK)** will release operating and financial results for the three and six months ended June 30, 2016, after the close of the U.S. financial markets on Monday, August 8, 2016.

OPKO's senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, August 8, 2016.

The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at [www.opko.com](http://www.opko.com) at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

## CONFERENCE CALL & WEBCAST INFORMATION

WHEN: Monday, August 8, 2016, 4:30 p.m. ET  
DOMESTIC DIAL-IN: (866) 634-2258  
INTERNATIONAL DIAL-IN: (330) 863-3454  
PASSCODE: 56394307

For those unable to participate in the conference call or webcast, a replay will be available beginning August 8, 2016 at 7:30 p.m. ET for a period of time. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 56394307.

The replay can also be accessed for a period of time on OPKO's website at [www.opko.com](http://www.opko.com).

## About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore<sup>®</sup> prostate cancer test and the Claros<sup>®</sup>1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, and VARUBI<sup>™</sup> for chemotherapy induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA date: January 2017). Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long acting Factor VIIa drug for hemophilia (Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at [www.opko.com](http://www.opko.com).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160803006232/en/>

**OPKO Health, Inc.:**

*Tara Mackay, 305-575-4100*

*Investor Relations*

or

**Media:**

*Rooney & Associates*

*Terry Rooney, 212-223-0689*

[trooney@rooneyco.com](mailto:trooney@rooneyco.com)

or

*Marion Janic, 212-223-4017*

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

or

**Investors:**

*LHA*

*Anne Marie Fields, 212-838-3777*

[afields@lhai.com](mailto:afields@lhai.com)

or

*Bruce Voss, 310-691-7100*

[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: OPKO Health, Inc.